GlassScriptPhysician profile
Andrew J Cottingham
NPI 1003893819
$990.10
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $209 · 2021: $45.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $239.83 | 2019-2021 | |
| Abbott Laboratories | $236.66 | 2019-2020 | |
| Medtronic USA, INC. | $222.74 | 2019 | |
| Pfizer INC. | $57.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.47 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $31.84 | 2020 | |
| Nevro Corp. | $25.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.83 | 2019-2020 | |
| Si-Bone, INC. | $24.94 | 2019 | |
| Allergan, INC. | $15.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.13 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.15 | 2019 | |
| Lilly USA, LLC | $12.78 | 2019 | |
| Vertiflex, INC. | $11.86 | 2019 | |
| Spr Therapeutics, INC | $6.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Cottingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.